Hybride CAR's: macrofaagsignalering herbedraden voor gerichte niertherapie

Chimeric antigen receptor (CAR) technology has reshaped modern cell therapy and remains one of the most influential advances in treatment for blood cancer, such as lymphoma, leukemia, and multiple myeloma.1 Although the field continues to refine CAR constructs to improve efficacy, safety, and accessibility, CAR platforms are now expanding into solid tumors, autoimmune diseases, and even infectious diseases.2,3 In addition, experimentally, CAR strategies, which are usually used in T cells, now also include the use of macrophages, whereby CAR macrophages (CAR-Ms) targeting β-amyloid have been shown to be beneficial in Alzheimer’s disease,4 whereas CAR-Ms targeting human epidermal growth factor receptor 2 have been shown to reduce tumor burden.